^
Association details:
Biomarker:MET overexpression
Cancer:Gastric Cancer
Drug:Xalkori (crizotinib) (ALK inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
Title:

Matched therapies for advanced gastric cancer based on genotype: A real-world study in China.

Published date:
05/19/2021
Excerpt:
...11 (37%) harbored c-MET amplification/overexpression (received savolitinib or crizotinib, cohort A)....three of 11 patients had an objective response (1 complete response and 2 partial responses, objective response rate (ORR) 27%), disease control rate (DCR) was 45%, median progression-free survival (mPFS) was 2.1 months, and median overall survival (mOS) was 3.7 months.